Dabrafenib and Trametinib in BRAF Mutant Metastatic Conjunctival Melanoma

Ernesto Rossi, Brigida Anna Maiorano, Monica Maria Pagliara, Maria Grazia Sammarco, Tommaso Dosa, Maurizio Martini, Guido Rindi, Emilio Bria, Maria Antonietta Blasi, Giampaolo Tortora, Giovanni Schinzari

Research output: Contribution to journalArticlepeer-review


Conjunctival melanoma is a rare primary ocular tumor. So far, no standard treatment exists for metastatic disease. Similarly to cutaneous melanoma, up to 50% of conjunctival melanomas harbor BRAF mutations. The most common is represented by V600E. Combined therapy with BRAF and MEK inhibitors is approved for BRAF mutant cutaneous metastatic melanomas. Herein, we report a case of a 70-years old patient with a metastatic conjunctival melanoma harboring V600E BRAF mutation successfully treated with dabrafenib and trametinib.

Original languageEnglish
Pages (from-to)232
JournalFrontiers in Oncology
Publication statusPublished - 2019


Dive into the research topics of 'Dabrafenib and Trametinib in BRAF Mutant Metastatic Conjunctival Melanoma'. Together they form a unique fingerprint.

Cite this